Rocket Doctor is now in-network with Aetna, having been fully credentialed for Medicare and Commercial insurance in New York State. Aetna is one of the nation’s largest health insurers, covering 39 million members across 16 states. Aetna members in New York now have in-network access to Rocket Doctor’s providers and digital health platform, including urgent care, chronic disease management, preventive and mental health services. Rocket Doctor is already active in New York through its partnership with Engag ...

Core Insights - Rocket Doctor AI Inc. reported its first significant revenue quarter in Q2 2025, generating $0.5 million, primarily due to the acquisition of Rocket Doctor Inc. [5][6] - The company completed the acquisition of Rocket Doctor Inc. on April 10, 2025, enhancing its digital health platform and expanding its operational capabilities [4][12] - The company is focusing on U.S. expansion and has secured new contracts, including a virtual-care partnership with Central California Alliance for Health, serving approximately 450,000 members [5][23] Financial Highlights - Q2 2025 revenue was $0.5 million, compared to $0 in Q1 2025 and Q2 2024, marking a significant increase attributed to the Rocket Doctor acquisition [6] - Gross margin for Q2 2025 was 89%, a notable improvement from 0% in previous quarters, driven by revenue from the digital health platform [6][27] - The net comprehensive loss for Q2 2025 was $2.7 million, or $0.04 per share, consistent with the loss reported in Q1 2025 but an improvement from $2.7 million or $0.07 per share in Q2 2024 [6][27] Corporate Developments - The company has shifted its business model from B2C to B2B, aligning with the demand for AI-driven solutions in healthcare systems and academic institutions [8] - The Global Library of Medicine (GLM) is central to the company's strategy, providing clinical decision support and educational tools [7][21] - The company has made significant investments in enhancing its platform architecture and API capabilities, positioning itself for accelerated commercialization [24] Market Opportunity - The global AI healthcare market is projected to exceed USD $180 billion by 2030, driven by the demand for efficiency and accuracy in clinical workflows [9] - The conversational AI segment is expected to grow from approximately USD $13.5 billion in 2024 to between USD $49 billion and $123 billion by 2030, indicating a ~24% CAGR [9] Product Development - The Medical Education Suite (MES) was successfully deployed to 240 medical students at the University of Minnesota, showcasing the potential of AI-driven tools in medical education [15][24] - Rocket Doctor's technology solutions, including Starship EMR and RD Connect, are designed to streamline workflows and reduce care delivery costs [12][19] - The company is actively developing an AI Pharmacy Assistant, with integration plans involving over 20 pharmacies [18]

Core Viewpoint - Rocket Doctor AI Inc. has successfully closed a non-brokered private placement, raising a total of C$4,234,700 through the issuance of special warrants and units, which will support its expansion plans in the U.S. market [1][2]. Group 1: Offering Details - The company closed a private placement of 3,677,400 special warrants at C$0.50 each, raising C$1,838,700, and 4,792,000 units at the same price, raising C$2,396,000 [1]. - Each unit consists of one common share and one share purchase warrant, with the warrant exercisable at C$0.75 for 12 months [2]. - The special warrants will convert into units automatically on the earlier of the filing of a prospectus supplement or four months and one day after issuance [3]. Group 2: Financial Use and Fees - Proceeds from the offering will be allocated for sales and administrative expenses, software research and development, and working capital [5]. - The company paid finder’s fees totaling C$201,616 and issued 403,232 broker warrants, each allowing the purchase of one share at C$0.75 for 12 months [4]. Group 3: Company Overview - Rocket Doctor AI Inc. provides AI-powered healthcare solutions, aiming to enhance access to quality healthcare through its proprietary technology, including the Global Library of Medicine [8]. - The company has facilitated over 700,000 patient visits through its platform, empowering physicians to manage their practices more efficiently [8]. - The focus is on reaching underserved communities in Canada and supporting patients on Medicaid and Medicare in the U.S. [9].

VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the "Company" or "Treatment") is pleased to announce that it is rebranding and reincorporating as Rocket Doctor AI Inc. This milestone reflects the Company's continued evolution and its commitment to advancing its strategic vision. Concurrently with the completion of the proposed name change, the Company's trading symbol on the Canadian Securities Exchange will be changed from "TRUE" ...

As Ontario's healthcare system evolves, Rocket Doctor remains focused on strengthening access, supporting physician-led care, and leveraging technology to meet the needs of patients, especially those in regions hit hardest by provider shortages and system gaps. 2024 marked the worst year on record for ER closures in Ontario, with 1 in 5 hospitals experiencing unplanned shutdowns, especially in rural areas. Ontario's family physician workforce is aging, with 15% of patients attached to doctors nearing retire ...

Group 1 - Treatment.com AI Inc. has engaged Independent Trading Group (ITG) for market-making services to enhance liquidity and maintain a reasonable market for its shares on the Canadian Securities Exchange (CSE) [1][2] - ITG will receive a monthly compensation of CAD $5,500, with the agreement initially set for one month and renewable monthly unless terminated with 30 days' notice [2] - ITG is a Toronto-based dealer-member specializing in market making and liquidity provision, established in 1992, and utilizes proprietary technology for high-quality execution services [3] Group 2 - Treatment.com AI is focused on improving healthcare through AI and clinical practices, having developed the Global Library of Medicine (GLM) with input from healthcare professionals [4] - The GLM includes over 10,000 expert medical reviews, providing clinical information, recommended tests, and billing codes to support healthcare professionals and reduce their administrative burden [4] - The platform aims to enhance patient care and support disenfranchised communities by allowing healthcare professionals to spend more time with patients [4]

Core Points - Treatment.com AI Inc. has engaged Independent Trading Group (ITG) for market-making services to enhance liquidity and maintain a reasonable market for its shares [1][2] - ITG will receive a monthly compensation of CAD $5,500, with the agreement set for an initial term of one month and automatic renewals unless terminated [2] - ITG is a Toronto-based dealer-member specializing in market making and liquidity provision, established in 1992 [3] Company Overview - Treatment.com AI Inc. utilizes AI and clinical best practices to address inefficiencies in the healthcare sector [4] - The company has developed the Global Library of Medicine (GLM), which includes over 10,000 expert medical reviews to support healthcare professionals [4] - The GLM aims to reduce administrative burdens for healthcare providers and improve patient care quality, while also including disenfranchised communities [4]

Core Viewpoint - Treatment.com AI Inc. is initiating a non-brokered private placement to raise up to C$3 million due to strong interest from investors, offering special warrants and units at C$0.50 each [1][5]. Group 1: Offering Details - The offering consists of special warrants and units, with each unit comprising one common share and one common share purchase warrant [1]. - Each warrant allows the holder to acquire one share at C$0.75 for 12 months following issuance [1]. - Special warrants will automatically convert into units on the earlier of the filing of a prospectus supplement or four months and one day after issuance [2]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized for working capital purposes [5]. Group 3: Conditions and Fees - The offering is expected to close by August 18, 2025, and is subject to necessary approvals, including from the Canadian Securities Exchange [5]. - The company may pay a finder's fee of up to 8% of gross proceeds and issue broker warrants equal to 8% of the number of special warrants and/or units sold [4]. Group 4: Company Overview - Treatment.com AI is focused on improving healthcare through AI and best clinical practices, with a comprehensive healthcare AI engine known as the Global Library of Medicine (GLM) [7]. - The GLM provides clinical information and support to healthcare professionals, helping to reduce administrative burdens and improve patient care [7].

Core Viewpoint - Treatment.com AI Inc. is initiating a non-brokered private placement to raise up to C$3 million due to strong interest from investors, offering special warrants and units at C$0.50 each [1][5]. Group 1: Offering Details - The offering consists of special warrants and units, with each unit comprising one common share and one common share purchase warrant [1]. - Each warrant allows the holder to acquire one share at a price of C$0.75 for 12 months following issuance [1]. - Special warrants will automatically convert into units on the earlier of the filing of a prospectus supplement or four months and one day after issuance [2]. Group 2: Use of Proceeds - The proceeds from the offering will be utilized for working capital purposes [5]. Group 3: Conditions and Fees - The offering is expected to close on or before August 18, 2025, and is subject to necessary approvals, including from the Canadian Securities Exchange [5]. - The company may pay a finder's fee of up to 8% of the gross proceeds and issue broker warrants equal to 8% of the number of special warrants and/or units sold [4]. Group 4: Company Overview - Treatment.com AI Inc. leverages AI to enhance healthcare delivery, addressing inefficiencies through its Global Library of Medicine, which includes over 10,000 expert medical reviews [7].

Core Viewpoint - Treatment.com AI Inc. has engaged two firms, 45 Degrees and Investment Publishing, to enhance its digital marketing and investor relations efforts, aiming to increase awareness and reach within the healthcare sector [1][4]. Group 1: Engagement with 45 Degrees - Treatment has contracted 45 Degrees for a six-month marketing engagement starting July 18, 2025, with a total fee of USD $180,000, payable in two installments [2]. - The marketing services include Google Ads, social media, and video interview distribution, with an option to extend the engagement on a month-to-month basis for USD $25,000 [2]. - Treatment has issued 400,000 stock options to the principal of 45 Degrees, exercisable at $0.45 per share for three years [3]. Group 2: Engagement with Investment Publishing - Treatment has engaged Investment Publishing for an initial one-year term to enhance its investor relations strategy, focusing on increasing company awareness [4]. - The engagement includes public relations efforts, educational content, and direct outreach through various digital platforms [4]. - Investment Publishing will also receive 400,000 stock options, exercisable at $0.45 per share for three years [4]. Group 3: Additional Option Grants - Treatment has granted an additional 400,000 stock options to certain arm's length consultants, also exercisable at $0.45 per share for three years [5]. Group 4: Company Overview - Treatment.com AI utilizes artificial intelligence to improve healthcare sector efficiencies, with a comprehensive AI engine known as the Global Library of Medicine (GLM) [6]. - The GLM provides over 10,000 expert medical reviews and supports healthcare professionals by reducing administrative burdens and improving patient care [6].